

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Broncus Holding Corporation

壑博医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2216)

VOLUNTARY ANNOUNCEMENT

BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and the potential investors of the latest updates of the business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has completed the first case of registered clinical trials of its targeted lung denervation (“**TLD**”) radiofrequency ablation system. The multi-center clinical randomized controlled trial on the “treatment of Chronic Obstructive Pulmonary Disease (“**COPD**”) by targeted lung denervation ablation through bronchoscopy” was led by Professor Luo Fengming at the West China Hospital of Sichuan University. The study will be conducted in 26 centers of China, and it will cover the safety and effectiveness of the targeted denervation ablation system of the Company in the treatment of COPD. The system is expected to be well-received by patients with COPD worldwide. The clinical operation was completed by a team consisting of Professor Liu Dan, at the Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University.

COPD is referred to as common chronic respiratory disease. According to Frost & Sullivan, there were 219.2 million COPD patients worldwide in 2020. According to the existing epidemiological evidence, the prevalence rate of COPD in adults over 40 years old is about 13.7% whereas some patients have very limited benefit from medication treatments.

TLD, a bronchoscopic radiofrequency ablation therapy for COPD, which is an internationally leading emerging technology. It mainly realizes denervation through targeted deep in lung tissue radiofrequency ablation in the areas rich in bronchial vagus nerves, thus reducing the airway obstruction of the whole lung and achieving the effect of COPD treatment. It was officially included in the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) on November 15, 2022.

ABOUT BRONCUS

The Company is a pioneer in the interventional pulmonology medical device market, provides innovative lung solutions in China and globally. Founded in 2012, the Company has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center. Through close ties with key opinion leaders in the global respiratory interventional field and the establishment of a comprehensive relationship from innovative concepts to project development and implementation, the Company has built a respiratory interventional diagnosis and treatment product pipeline comprises of 18 products and major product candidates, and owned a diversified intellectual property portfolio of 773 patents and patent applications. In addition, the Company through clinical training and market education and with its strong brand promotion and commercialization capabilities, has sales to mainstream markets around the world such as the United States, Europe, and Australia.

Forward Looking Statement

There is no assurance that the TLD radiofrequency ablation system will ultimately be successfully developed or marketed by the Company. There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
Broncus Holding Corporation
ZHAO Michael Yi Wei
Chairman

Hong Kong, July 10, 2023

As at the date of this announcement, the Board comprises Mr. ZHAN Guowei and Mr. XU Hong as executive Directors, Mr. ZHAO Michael Yi Wei as Chairman and non-executive Director, Mr. ZI Zhenjun and Mr. ZHANG Ao as non-executive Directors, and Dr. KAM Pok Man, Professor LAU Joseph Wan Yee and Ms. WONG Yee Sin as independent non-executive Directors.